{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T01:09:43Z","timestamp":1789088983199,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jtha.2026.08.010","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T16:09:06Z","timestamp":1787155746000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Factor IX gene variants may influence the pharmacokinetic profile of patients with hemophilia B treated with Factor IX-fusion protein or N9-GP extended half-life Factor IX concentrates"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9902-4074","authenticated-orcid":false,"given":"Davide","family":"Matino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2291-982X","authenticated-orcid":false,"given":"Zainab","family":"Al-Housni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Samelson-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Chelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Castaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Teitel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lillicrap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Keepanasseril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyumin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Edginton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Iorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2026.08.010_bib1","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1182\/bloodadvances.2016002923","article-title":"Novel approach to genetic analysis and results in 3000 hemophilia patients enrolled in the My Life, Our Future initiative","volume":"1","author":"Johnsen","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2026.08.010_bib2","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1160\/TH16-12-0942","article-title":"Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates","volume":"117","author":"Iorio","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.010_bib3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3390\/jcm6030035","article-title":"The history of clotting factor concentrates pharmacokinetics","volume":"6","author":"Morfini","year":"2017","journal-title":"J Clin Med"},{"key":"10.1016\/j.jtha.2026.08.010_bib4","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s40262-013-0129-7","article-title":"Population pharmacokinetic modelling of recombinant factor IX Fc fusion protein (rFIXFc) in patients with haemophilia B","volume":"53","author":"Diao","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jtha.2026.08.010_bib5","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/hae.14078","article-title":"Biological mechanisms underlying inter-individual variation in factor VIII clearance in haemophilia","volume":"26","author":"Turecek","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2026.08.010_bib6","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1111\/jth.15395","article-title":"Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: data from the WAPPS database","volume":"19","author":"Versloot","year":"2021","journal-title":"J Thromb Haemost JTH"},{"key":"10.1016\/j.jtha.2026.08.010_bib7","doi-asserted-by":"crossref","first-page":"16717","DOI":"10.1074\/jbc.272.27.16717","article-title":"Human factor IX binds to specific sites on the collagenous domain of collagen IV","volume":"272","author":"Wolberg","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jtha.2026.08.010_bib8","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1365-2141.1987.tb01303.x","article-title":"In vivo evidence of intravascular binding sites for coagulation factor IX","volume":"66","author":"Stern","year":"1987","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2026.08.010_bib9","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1111\/jth.12421","article-title":"Evidence of clinically significant extravascular stores of factor IX","volume":"11","author":"Feng","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.010_bib10","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1182\/blood.2018884015","article-title":"Dysfunctional endogenous FIX impairs prophylaxis in a mouse hemophilia B model","volume":"133","author":"Cooley","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.08.010_bib11","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1182\/blood-2011-02-335596","article-title":"Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B","volume":"118","author":"Negrier","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.08.010_bib12","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood-2011-07-367003","article-title":"Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1\/2a study in hemophilia B patients","volume":"119","author":"Shapiro","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.08.010_bib13","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1002\/psp4.13159","article-title":"PBPK modeling of recombinant factor IX Fc fusion protein (rFIXFc) and rFIX to characterize the binding to type 4 collagen in the extravascular space","volume":"13","author":"Cloesmeijer","year":"2024","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"10.1016\/j.jtha.2026.08.010_bib14","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/hae.14300","article-title":"The Function of extravascular coagulation factor IX in haemostasis","volume":"27","author":"Mann","year":"2021","journal-title":"Haemoph Off J World Fed Hemoph"},{"key":"10.1016\/j.jtha.2026.08.010_bib15","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1182\/blood-2011-02-336172","article-title":"Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide","volume":"118","author":"\u00d8stergaard","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.08.010_bib16","doi-asserted-by":"crossref","DOI":"10.2196\/resprot.6558","article-title":"Development of a web-accessible population pharmacokinetic service\u2014hemophilia (WAPPS-Hemo): study protocol","volume":"5","author":"Iorio","year":"2016","journal-title":"JMIR Res Protoc"},{"key":"10.1016\/j.jtha.2026.08.010_bib17","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/hae.13977","article-title":"Development and evaluation of the population pharmacokinetic models for FVIII and FIX concentrates of the WAPPS-Hemo project","volume":"26","author":"Hajducek","year":"2020","journal-title":"Haemophilia"},{"issue":"5","key":"10.1016\/j.jtha.2026.08.010_bib18","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jtha.2023.02.005","article-title":"An updated interactive database for 1692 genetic variants in coagulation factor IX provides detailed insights into hemophilia B","volume":"21","author":"Xu","year":"2023","journal-title":"J Thromb Haemost JTH"},{"key":"10.1016\/j.jtha.2026.08.010_bib19","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1182\/blood.2023021944","article-title":"Enhanced procoagulant activity of select hemophilia B causing factor IX variants with emicizumab","volume":"144","author":"Lee","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.08.010_bib20","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1182\/bloodadvances.2019000405","article-title":"Evolutionary insights into coagulation factor IX Padua and other high-specific-activity variants","volume":"5","author":"Samelson-Jones","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2026.08.010_bib21","author":"Popp"},{"key":"10.1016\/j.jtha.2026.08.010_bib22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12959-016-0104-2","article-title":"Extravascular FIX and coagulation","volume":"14","author":"Stafford","year":"2016","journal-title":"Thromb J"},{"key":"10.1016\/j.jtha.2026.08.010_bib23","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2147\/JBM.S389094","article-title":"Efficacy of rFIXFc versus N9-GP prophylaxis in patients with hemophilia B: matching-adjusted indirect comparison of B-LONG and PARADIGM 2 trials","volume":"14","author":"Mancuso","year":"2023","journal-title":"J Blood Med"},{"key":"10.1016\/j.jtha.2026.08.010_bib24","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/MBC.0000000000001230","article-title":"Biodistribution of recombinant factor IX, extended half-life recombinant factor IX Fc fusion protein, and glycoPEGylated recombinant factor IX in hemophilia B mice","volume":"34","author":"Van Der Flier","year":"2023","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jtha.2026.08.010_bib25","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/rth2.12192","article-title":"Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX-Fc fusion protein: a randomized trial","volume":"3","author":"Escuriola Ettingshausen","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.010_bib26","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1016\/j.jtha.2025.04.025","article-title":"\u201cAn integrated multitool analysis contributes elements to interpreting unclassified factor IX missense variants associated with hemophilia B\u201d: comment from Lee et al","volume":"23","author":"Lee","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.010_bib27","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1016\/j.jtha.2024.07.008","article-title":"An integrated multitool analysis contributes elements to interpreting unclassified factor IX missense variants associated with hemophilia B","volume":"22","author":"Sacco","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.010_bib28","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.1111\/hae.13943","article-title":"Spontaneous bleeding and poor bleeding response with extended half-life factor IX products: a survey of select US haemophilia treatment centres","volume":"26","author":"Malec","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2026.08.010_bib29","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1111\/hae.13896","article-title":"Excessive breakthrough bleeding in haemophilia B patients on factor IX-albumin fusion protein prophylactic therapy: a single centre case series","volume":"26","author":"Kleiboer","year":"2020","journal-title":"Haemophilia"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626005325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626005325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:50:15Z","timestamp":1789087815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783626005325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":29,"alternative-id":["S1538783626005325"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2026.08.010","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factor IX gene variants may influence the pharmacokinetic profile of patients with hemophilia B treated with Factor IX-fusion protein or N9-GP extended half-life Factor IX concentrates","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2026.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}